Praxis Precision Medicines to Host Conference Call to Announce Topline Results from the RADIANT Trial and Provide Second Quarter 2025 Financial Results

BOSTON, July 29, 2025 (GLOBE NEWSWIRE) — Praxis Precision Medicines, Inc. (NASDAQ: PRAX), a clinical-stage biopharmaceutical company translating genetic insights into the development of therapies for central nervous system (CNS) disorders characterized by neuronal excitation-inhibition imbalance, today announced it will report topline results from the RADIANT trial of vormatrigine and its financial results from the second quarter ended June 30, 2025, before the financial markets open on Monday, August 4, 2025.

The Company will host a live webcast the same morning at 8:30am ET, which can be accessed by visiting this registration link. This live webcast will also be available through the Events & Presentations page of the Investors + Media section of the company’s website. A replay of the webcast will be available on Praxis’ website for 90 days following the event.

About Praxis
Praxis Precision Medicines is a clinical-stage biopharmaceutical company translating insights from genetic epilepsies into the development of therapies for CNS disorders characterized by neuronal excitation-inhibition imbalance. Praxis is applying genetic insights to the discovery and development of therapies for rare and more prevalent neurological disorders through our proprietary small molecule platform, Cerebrum™, and antisense oligonucleotide (ASO) platform, Solidus™, using our understanding of shared biological targets and circuits in the brain. Praxis has established a diversified, multimodal CNS portfolio including multiple programs across epilepsy and movement disorders, with four clinical-stage product candidates. For more information, please visit www.praxismedicines.com and follow us on FacebookLinkedIn and Twitter/X.

CONTACT: Investor Contact:
Praxis Precision Medicines
investors@praxismedicines.com
857-702-9452

Media Contact:
Dan Ferry
LifeSci Advisors
daniel@lifesciadvisors.com
617-430-7576

Staff

Recent Posts

Dräger PSS® AirBoss SCBA Now Available for Purchase in North America

Now Available for Purchase, AirBoss Delivers an NFPA 1970:2025 SCBA Built for the Way American…

4 hours ago

Greenway Health® Named Most Improved Physician Practice Solution 2026 by KLAS Research

KLAS recognition highlights Greenway's momentum in modernizing physician practice technologyTAMPA, Fla., Feb. 5, 2026 /PRNewswire/…

4 hours ago

Huckleberry Launches Berry: Specialized AI that Brings Family Context Front and Center

While AI booms, Berry delivers quiet confidence to parents by pairing each child's unique logged…

4 hours ago

AI Lab Goodfire Raises $150M at $1.25B Valuation to Design Models with Interpretability

SAN FRANCISCO, Feb. 5, 2026 /PRNewswire/ -- Today, Goodfire—the AI research lab using interpretability to…

4 hours ago

Nanorobotics Market worth $4.52 billion by 2032 – Exclusive Report by MarketsandMarkets™

DELRAY BEACH, Fla., Feb. 5, 2026 /PRNewswire/ -- According to MarketsandMarkets™, the global nanorobotics market…

4 hours ago

Vidle.com and LaborEdge Announce Strategic Integration to Streamline Healthcare Staffing Recruitment

Integration Delivers Faster Hiring, Qualified Candidates, and Zero Posting Fees for Healthcare Staffing AgenciesDELRAY BEACH,…

4 hours ago